A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients

George M. Nassar, Marc H. Glickman, Robert Mclafferty, J. Kevin Croston, Joseph I. Zarge, Howard E. Katzman, Eric K. Peden, Jeffrey H. Lawson, Jeffrey M. Martinez, Lisa Thackeray

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Venous stenosis and occlusion are a major cause of vascular access dysfunction and failure. The HeRO Graft bypasses occlusion and traverses stenosis with outflow directly into the central venous circulation. A randomized, multicenter study was conducted to evaluate the efficacy and safety of the HeRO Graft relative to conventional AV grafts. The design was to enroll 143 patients in a 2:1 randomization ratio between HeRO and conventional AV control groups. Data on 72 subjects (52 HeRO Graft and 20 AV graft controls) were obtained. The HeRO Graft and control cohorts were comparable in baseline characteristics. Adequacy of dialysis, bacteremia rates, and adverse events were consistent between groups. Twelve month Kaplan-Meier estimates for primary and secondary patency rates were 34.8% and 67.6% in the HeRO Graft cohort, and 30.6% and 58.4% in the control cohort. There was no statistical difference in terms of patency between groups. The rates of intervention were 2.2/year for HeRO Graft and 1.6/year for the control (p = 0.100). Median days to loss of secondary patency was 238 for HeRO Graft versus 102 for the control (p = 0.032). The HeRO Graft appears to provide similar patency, adequacy of dialysis, and bacteremia rates to those of conventional AV grafts.

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalSeminars in Dialysis
Volume27
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Renal Dialysis
Transplants
Bacteremia
Dialysis
Pathologic Constriction
Kaplan-Meier Estimate
Random Allocation
Multicenter Studies
Blood Vessels
Safety
Control Groups

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Nassar, G. M., Glickman, M. H., Mclafferty, R., Kevin Croston, J., Zarge, J. I., Katzman, H. E., ... Thackeray, L. (2014). A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients. Seminars in Dialysis, 27(3), 310-318. https://doi.org/10.1111/sdi.12173

A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients. / Nassar, George M.; Glickman, Marc H.; Mclafferty, Robert; Kevin Croston, J.; Zarge, Joseph I.; Katzman, Howard E.; Peden, Eric K.; Lawson, Jeffrey H.; Martinez, Jeffrey M.; Thackeray, Lisa.

In: Seminars in Dialysis, Vol. 27, No. 3, 2014, p. 310-318.

Research output: Contribution to journalArticle

Nassar, GM, Glickman, MH, Mclafferty, R, Kevin Croston, J, Zarge, JI, Katzman, HE, Peden, EK, Lawson, JH, Martinez, JM & Thackeray, L 2014, 'A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients', Seminars in Dialysis, vol. 27, no. 3, pp. 310-318. https://doi.org/10.1111/sdi.12173
Nassar, George M. ; Glickman, Marc H. ; Mclafferty, Robert ; Kevin Croston, J. ; Zarge, Joseph I. ; Katzman, Howard E. ; Peden, Eric K. ; Lawson, Jeffrey H. ; Martinez, Jeffrey M. ; Thackeray, Lisa. / A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients. In: Seminars in Dialysis. 2014 ; Vol. 27, No. 3. pp. 310-318.
@article{2ab15010fb6c4943aad02e6eb44d5e11,
title = "A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients",
abstract = "Venous stenosis and occlusion are a major cause of vascular access dysfunction and failure. The HeRO Graft bypasses occlusion and traverses stenosis with outflow directly into the central venous circulation. A randomized, multicenter study was conducted to evaluate the efficacy and safety of the HeRO Graft relative to conventional AV grafts. The design was to enroll 143 patients in a 2:1 randomization ratio between HeRO and conventional AV control groups. Data on 72 subjects (52 HeRO Graft and 20 AV graft controls) were obtained. The HeRO Graft and control cohorts were comparable in baseline characteristics. Adequacy of dialysis, bacteremia rates, and adverse events were consistent between groups. Twelve month Kaplan-Meier estimates for primary and secondary patency rates were 34.8{\%} and 67.6{\%} in the HeRO Graft cohort, and 30.6{\%} and 58.4{\%} in the control cohort. There was no statistical difference in terms of patency between groups. The rates of intervention were 2.2/year for HeRO Graft and 1.6/year for the control (p = 0.100). Median days to loss of secondary patency was 238 for HeRO Graft versus 102 for the control (p = 0.032). The HeRO Graft appears to provide similar patency, adequacy of dialysis, and bacteremia rates to those of conventional AV grafts.",
author = "Nassar, {George M.} and Glickman, {Marc H.} and Robert Mclafferty and {Kevin Croston}, J. and Zarge, {Joseph I.} and Katzman, {Howard E.} and Peden, {Eric K.} and Lawson, {Jeffrey H.} and Martinez, {Jeffrey M.} and Lisa Thackeray",
year = "2014",
doi = "10.1111/sdi.12173",
language = "English (US)",
volume = "27",
pages = "310--318",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients

AU - Nassar, George M.

AU - Glickman, Marc H.

AU - Mclafferty, Robert

AU - Kevin Croston, J.

AU - Zarge, Joseph I.

AU - Katzman, Howard E.

AU - Peden, Eric K.

AU - Lawson, Jeffrey H.

AU - Martinez, Jeffrey M.

AU - Thackeray, Lisa

PY - 2014

Y1 - 2014

N2 - Venous stenosis and occlusion are a major cause of vascular access dysfunction and failure. The HeRO Graft bypasses occlusion and traverses stenosis with outflow directly into the central venous circulation. A randomized, multicenter study was conducted to evaluate the efficacy and safety of the HeRO Graft relative to conventional AV grafts. The design was to enroll 143 patients in a 2:1 randomization ratio between HeRO and conventional AV control groups. Data on 72 subjects (52 HeRO Graft and 20 AV graft controls) were obtained. The HeRO Graft and control cohorts were comparable in baseline characteristics. Adequacy of dialysis, bacteremia rates, and adverse events were consistent between groups. Twelve month Kaplan-Meier estimates for primary and secondary patency rates were 34.8% and 67.6% in the HeRO Graft cohort, and 30.6% and 58.4% in the control cohort. There was no statistical difference in terms of patency between groups. The rates of intervention were 2.2/year for HeRO Graft and 1.6/year for the control (p = 0.100). Median days to loss of secondary patency was 238 for HeRO Graft versus 102 for the control (p = 0.032). The HeRO Graft appears to provide similar patency, adequacy of dialysis, and bacteremia rates to those of conventional AV grafts.

AB - Venous stenosis and occlusion are a major cause of vascular access dysfunction and failure. The HeRO Graft bypasses occlusion and traverses stenosis with outflow directly into the central venous circulation. A randomized, multicenter study was conducted to evaluate the efficacy and safety of the HeRO Graft relative to conventional AV grafts. The design was to enroll 143 patients in a 2:1 randomization ratio between HeRO and conventional AV control groups. Data on 72 subjects (52 HeRO Graft and 20 AV graft controls) were obtained. The HeRO Graft and control cohorts were comparable in baseline characteristics. Adequacy of dialysis, bacteremia rates, and adverse events were consistent between groups. Twelve month Kaplan-Meier estimates for primary and secondary patency rates were 34.8% and 67.6% in the HeRO Graft cohort, and 30.6% and 58.4% in the control cohort. There was no statistical difference in terms of patency between groups. The rates of intervention were 2.2/year for HeRO Graft and 1.6/year for the control (p = 0.100). Median days to loss of secondary patency was 238 for HeRO Graft versus 102 for the control (p = 0.032). The HeRO Graft appears to provide similar patency, adequacy of dialysis, and bacteremia rates to those of conventional AV grafts.

UR - http://www.scopus.com/inward/record.url?scp=84899472294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899472294&partnerID=8YFLogxK

U2 - 10.1111/sdi.12173

DO - 10.1111/sdi.12173

M3 - Article

C2 - 24428351

AN - SCOPUS:84899472294

VL - 27

SP - 310

EP - 318

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 3

ER -